Literature DB >> 26291195

Marked Strain-Specific Differences in the SU5416 Rat Model of Severe Pulmonary Arterial Hypertension.

Baohua Jiang1, Yupu Deng1, Colin Suen1,2, Mohamad Taha1,2, Ketul R Chaudhary1, David W Courtman1, Duncan J Stewart1,2.   

Abstract

We assessed the pulmonary hemodynamic response to vascular endothelial growth factor receptor, type 2, inhibition using SU5416 (SU) with and without chronic hypoxia (CH) in different background strains and colonies of rats. A single subcutaneous injection of SU (20 mg/kg) or vehicle was administered to different substrains of Sprague-Dawley (SD) rats, and they were compared with Lewis and Fischer rats, with and without exposure to CH (10% O2 for 3 wk). Remarkably, a unique colony of SD rats from Charles River Laboratories, termed the SD-hyperresponsive type, exhibited severe pulmonary arterial hypertension (PAH) with SU alone, characterized by increased right ventricular systolic pressure, right ventricular/left ventricular plus septal weight ratio, and arteriolar occlusive lesions at 7-8 weeks (all P < 0.0001 versus vehicle). In contrast, the other SD substrain from Harlan Laboratories, termed SD-typical type, as well as Fischer rats, developed severe PAH only when exposed to SU and CH, whereas Lewis rats showed only a minimal response. All SD-typical type rats survived for up to 13 weeks after SU/CH, whereas SD-hyperresponsive type rats exhibited mortality after SU and SU/CH (35% and 50%, respectively) at 8 weeks. Fischer rats exposed to SU/CH exhibited the greatest mortality at 8 weeks (78%), beginning as early as 4 weeks after SU and preceded by right ventricle enlargement. Of note, a partial recovery of PAH after 8 weeks was observed in the SD-typical type substrain only. In conclusion, variation in strain, even between colonies of the same strain, has a remarkable influence on the nature and severity of the response to SU, consistent with an important role for genetic modifiers of the PAH phenotype.

Entities:  

Keywords:  SU5416; pulmonary arterial hypertension; right ventricular remodeling; rodent strains; vascular remodeling

Mesh:

Substances:

Year:  2016        PMID: 26291195     DOI: 10.1165/rcmb.2014-0488OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  39 in total

1.  Ischemia-induced Drp1 and Fis1-mediated mitochondrial fission and right ventricular dysfunction in pulmonary hypertension.

Authors:  Lian Tian; Monica Neuber-Hess; Jeffrey Mewburn; Asish Dasgupta; Kimberly Dunham-Snary; Danchen Wu; Kuang-Hueih Chen; Zhigang Hong; Willard W Sharp; Shelby Kutty; Stephen L Archer
Journal:  J Mol Med (Berl)       Date:  2017-03-06       Impact factor: 4.599

2.  Comparing pulmonary hypertension severity between rat strains suggests right ventricle NK cells are protective.

Authors:  Claudia Mickael; Michael H Lee; Sue Gu; Brian B Graham
Journal:  Cardiovasc Res       Date:  2019-03-15       Impact factor: 10.787

3.  Efficacy of treprostinil in the SU5416-hypoxia model of severe pulmonary arterial hypertension: haemodynamic benefits are not associated with improvements in arterial remodelling.

Authors:  Ketul R Chaudhary; Yupu Deng; Colin M Suen; Mohamad Taha; Thomas H Petersen; Shirley H J Mei; Duncan J Stewart
Journal:  Br J Pharmacol       Date:  2018-09-16       Impact factor: 8.739

Review 4.  Translating Research into Improved Patient Care in Pulmonary Arterial Hypertension.

Authors:  Sébastien Bonnet; Steeve Provencher; Christophe Guignabert; Frédéric Perros; Olivier Boucherat; Ralph Theo Schermuly; Paul M Hassoun; Marlene Rabinovitch; Mark R Nicolls; Marc Humbert
Journal:  Am J Respir Crit Care Med       Date:  2017-03-01       Impact factor: 21.405

5.  Update in Pulmonary Vascular Disease 2016 and 2017.

Authors:  Evan L Brittain; Thennapan Thennapan; Bradley A Maron; Stephen Y Chan; Eric D Austin; Edda Spiekerkoetter; Harm J Bogaard; Christophe Guignabert; Roxane Paulin; Roberto F Machado; Paul B Yu
Journal:  Am J Respir Crit Care Med       Date:  2018-07-01       Impact factor: 21.405

6.  Evaluation of two-dimensional strain echocardiography for quantifying right ventricular function in patients with pulmonary arterial hypertension.

Authors:  Yong Liu; Yong Wang; Yingying Wang; Zhe Wen
Journal:  Exp Ther Med       Date:  2017-06-12       Impact factor: 2.447

Review 7.  Models and Molecular Mechanisms of World Health Organization Group 2 to 4 Pulmonary Hypertension.

Authors:  Ping Yu Xiong; Francois Potus; Winnie Chan; Stephen L Archer
Journal:  Hypertension       Date:  2017-11-20       Impact factor: 10.190

Review 8.  A pro-con debate: current controversies in PAH pathogenesis at the American Thoracic Society International Conference in 2017.

Authors:  Wolfgang M Kuebler; Mark R Nicolls; Andrea Olschewski; Kohtaro Abe; Marlene Rabinovitch; Duncan Stewart; Stephen Y Chan; Nicholas W Morrell; Stephen L Archer; Edda Spiekerkoetter
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-06-07       Impact factor: 5.464

9.  Impaired Pulmonary Arterial Vasoconstriction and Nitric Oxide-Mediated Relaxation Underlie Severe Pulmonary Hypertension in the Sugen-Hypoxia Rat Model.

Authors:  Helen Christou; Hannes Hudalla; Zoe Michael; Evgenia J Filatava; Jun Li; Minglin Zhu; Jose S Possomato-Vieira; Carlos Dias-Junior; Stella Kourembanas; Raouf A Khalil
Journal:  J Pharmacol Exp Ther       Date:  2017-12-06       Impact factor: 4.030

10.  Dominant Role for Regulatory T Cells in Protecting Females Against Pulmonary Hypertension.

Authors:  Rasa Tamosiuniene; Olga Manouvakhova; Paul Mesange; Toshie Saito; Jin Qian; Mrinmoy Sanyal; Yu-Chun Lin; Linh P Nguyen; Amir Luria; Allen B Tu; Joshua M Sante; Marlene Rabinovitch; Desmond J Fitzgerald; Brian B Graham; Aida Habtezion; Norbert F Voelkel; Laure Aurelian; Mark R Nicolls
Journal:  Circ Res       Date:  2018-03-15       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.